E. Régulier

发表

Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood

Mauro Delorenzi, Sarah J Tabrizi, Ruth Luthi-Carter, 2007, Proceedings of the National Academy of Sciences.

Inhibition of Calcineurin by FK506 Protects against Polyglutamine-Huntingtin Toxicity through an Increase of Huntingtin Phosphorylation at S421

N. Déglon, P. Aebischer, S. Humbert, 2006, The Journal of Neuroscience.

Cancer immunotherapy by direct in vivo transfer of immunomodulatory genes.

P. Leroy, P. Erbs, P. Devauchelle, 1998, Research in immunology.

Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.

A. Koeppen, N. Déglon, S. Simões, 2008, Human molecular genetics.

Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach

G. Cauet, S. Paul, D. Roecklin, 2001, Cancer Gene Therapy.

Tumor gene therapy by MVA-mediated expression of T-cell–stimulating antibodies

M. Kieny, S. Paul, E. Régulier, 2002, Cancer Gene Therapy.

Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity

E. Régulier, B. Wang, Z. Qin, 2002, Gene Therapy.

Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study.

E. Hunsche, J. Burke, E. Régulier, 2015, The American journal of managed care.

Phosphoribosyltransferase Fusion Gene Transfer of a Bifunctional Yeast Cytosine Deaminase / Uracil Cancer Gene Therapy by Adenovirus-mediated In Vivo

P. Leroy, P. Erbs, R. Jund, 2000 .

In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene.

P. Leroy, P. Erbs, M. Mehtali, 2000, Cancer research.

Improvement of mouse β-thalassemia upon erythropoietin delivery by encapsulated myoblasts

N. Déglon, P. Aebischer, P. Rouyer‐Fessard, 1999, Gene Therapy.

A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension.

N. Déglon, P. Aebischer, Y. Beuzard, 1997, Human gene therapy.

Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum.

N. Déglon, P. Aebischer, Y. Trottier, 2003, Human molecular genetics.

MAP Kinase Phosphatase 1 (MKP-1/DUSP1) Is Neuroprotective in Huntington's Disease via Additive Effects of JNK and p38 Inhibition

Darlene R Goldstein, Ruth Luthi-Carter, Lesley Jones, 2013, The Journal of Neuroscience.

Dysregulation of Gene Expression in Primary Neuron Models of Huntington's Disease Shows That Polyglutamine-Related Effects on the Striatal Transcriptome May Not Be Dependent on Brain Circuitry

Beate Sick, Ruth Luthi-Carter, Patrick Aebischer, 2008, The Journal of Neuroscience.

Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease.

N. Déglon, P. Aebischer, E. Brouillet, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Akt is altered in an animal model of Huntington's disease and in patients

A. Dürr, A. Brice, N. Déglon, 2005, The European journal of neuroscience.

Lentiviral-mediated gene transfer to model triplet repeat disorders.

N. Déglon, P. Aebischer, D. Zala, 2004, Methods in molecular biology.

Interactions between NEEP21, GRIP1 and GluR2 regulate sorting and recycling of the glutamate receptor subunit GluR2

D. Muller, P. Steiner, S. Alberi, 2005, The EMBO journal.

CA150 Expression Delays Striatal Cell Death in Overexpression and Knock-In Conditions for Mutant Huntingtin Neurotoxicity

Christian Néri, Ronald Wetzel, Emmanuel Brouillet, 2006, The Journal of Neuroscience.

Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease.

H. D. Rosas, D. Housman, S. Hersch, 2009, Analytical biochemistry.

Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease.

S. Lindquist, T. Iwatsubo, P. Aebischer, 2008, The Journal of clinical investigation.

Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease.

N. Déglon, P. Aebischer, L. Pereira de Almeida, 2002, Human gene therapy.

The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer

E. Régulier, B. Acres, Y. Poitevin, 2002, Cancer Immunology, Immunotherapy.

Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo

C. Pagès, J. Caboche, N. Déglon, 2008, Neurobiology of Disease.

Diminished hippocalcin expression in Huntington’s disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons

N. Déglon, O. Gokce, R. Luthi-Carter, 2009, Journal of neurochemistry.

PSY154 - ECONOMIC BURDEN OF BETA-THALASSEMIA: LITERATURE REVIEW

A. Kotzeva, E. Régulier, E. Druyts, 2018, Value in Health.

Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington’s disease

G. Bates, M. Bibel, B. Woodman, 2007, Journal of neurochemistry.

[Tumor-induced immunosuppression].

E. Régulier, B. Calmels, S. Paul, 2002, Annales de biologie clinique.

Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts

P Aebischer, N. Déglon, P. Aebischer, 1998, Gene Therapy.

Cost of a Pulmonary Arterial Hypertension-Related Hospitalization in Belgium.

E. Hunsche, P. Chevalier, M. Lamotte, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.